236 related articles for article (PubMed ID: 29499048)
1. In vitro immunotherapy potency assays using real-time cell analysis.
Cerignoli F; Abassi YA; Lamarche BJ; Guenther G; Santa Ana D; Guimet D; Zhang W; Zhang J; Xi B
PLoS One; 2018; 13(3):e0193498. PubMed ID: 29499048
[TBL] [Abstract][Full Text] [Related]
2. The xCELLigence system for real-time and label-free monitoring of cell viability.
Ke N; Wang X; Xu X; Abassi YA
Methods Mol Biol; 2011; 740():33-43. PubMed ID: 21468966
[TBL] [Abstract][Full Text] [Related]
3. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
[TBL] [Abstract][Full Text] [Related]
5. Real-time cell analysis (RTCA) to measure killer cell activity against adherent tumor cells in vitro.
Oberg HH; Peters C; Kabelitz D; Wesch D
Methods Enzymol; 2020; 631():429-441. PubMed ID: 31948561
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
7. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells.
Peper JK; Schuster H; Löffler MW; Schmid-Horch B; Rammensee HG; Stevanović S
J Immunol Methods; 2014 Mar; 405():192-8. PubMed ID: 24486140
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
9. Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology.
Moodley K; Angel CE; Glass M; Graham ES
J Neurosci Methods; 2011 Sep; 200(2):173-80. PubMed ID: 21781988
[TBL] [Abstract][Full Text] [Related]
10. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
12. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
[TBL] [Abstract][Full Text] [Related]
14. Reuse of E-plate cell sensor arrays in the xCELLigence Real-Time Cell Analyzer.
Stefanowicz-Hajduk J; Adamska A; Bartoszewski R; Ochocka JR
Biotechniques; 2016; 61(3):117-22. PubMed ID: 27625205
[TBL] [Abstract][Full Text] [Related]
15. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
16. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
[TBL] [Abstract][Full Text] [Related]
17. Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy.
de Wolf C; van de Bovenkamp M; Hoefnagel M
Cytotherapy; 2018 May; 20(5):601-622. PubMed ID: 29598903
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
19. Increase in peripheral blood mononuclear cell (PBMC)- and CD56+ cell-mediated killing of endometrial stromal cells by mycobacteria; a possible role in endometriosis immunotherapy?
Clayton RD; Duffy SR; Wilkinson N; Garry R; Jackson AM
Hum Reprod; 2004 Aug; 19(8):1886-93. PubMed ID: 15178662
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor.
Lee HW; Singh TD; Lee SW; Ha JH; Rehemtulla A; Ahn BC; Jeon YH; Lee J
FASEB J; 2014 Jul; 28(7):2932-41. PubMed ID: 24736413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
